Desai et al., Circulation 2013

Nov 13, 2014

10 likes | 157 Vues

Lp(a) reduction after different dosing schemes of PCSK9 inhibition. AMG 145 Q2W. AMG 145 Q4W. 0. 70mg (n=75). 105mg (n=76). 140mg (n=73). 280mg (n=78). 350mg (n=79). 420mg (n=77). -10. -18.2. -18.0. LS Mean % change in Lp(a) from baseline to week 12. -20. -22.8.

quincy-morrow

Télécharger la présentation

Desai et al., Circulation 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Lp(a) reductionafter different dosingschemes of PCSK9 inhibition AMG 145 Q2W AMG 145 Q4W 0 70mg (n=75) 105mg (n=76) 140mg (n=73) 280mg (n=78) 350mg (n=79) 420mg (n=77) -10 -18.2 -18.0 LS Mean % change in Lp(a) from baseline to week 12 -20 -22.8 -23.1 -18 -30 -32.1 -32.3 -40 P<0.001 foreachdose vs. placebo P<0.001 foreachdose vs. placebo Desaiet al., Circulation 2013